Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Cash Flow-to-Debt Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Cash Flow-to-Debt Ratio of 0.09x as of September 2025, meaning its operating cash flow of CN¥61.35 Million could theoretically repay 0% of its total liabilities (CN¥692.94 Million) in one year. See financial agility of Chengdu Easton Biopharmaceuticals Co Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chengdu Easton Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Chengdu Easton Biopharmaceuticals Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Chengdu Easton Biopharmaceuticals Co Ltd. Check Chengdu Easton Biopharmaceuticals Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.37x | CN¥263.24 Million | CN¥702.21 Million | ▲ +1.2% |
| 2023 | 0.37x | CN¥275.25 Million | CN¥743.33 Million | ▲ +39.7% |
| 2022 | 0.27x | CN¥151.94 Million | CN¥573.08 Million | ▼ -13.1% |
| 2021 | 0.31x | CN¥147.60 Million | CN¥483.60 Million | ▼ -15.1% |
| 2020 | 0.36x | CN¥156.52 Million | CN¥435.61 Million | ▼ -26.6% |
| 2019 | 0.49x | CN¥141.83 Million | CN¥289.64 Million | ▼ -39.1% |
| 2018 | 0.80x | CN¥166.79 Million | CN¥207.50 Million | ▲ +37.6% |
| 2017 | 0.58x | CN¥85.70 Million | CN¥146.70 Million | ▼ -28.2% |
| 2016 | 0.81x | CN¥106.06 Million | CN¥130.43 Million | ▼ -30.2% |
| 2015 | 1.16x | CN¥50.57 Million | CN¥43.42 Million | ▲ +99.1% |
| 2014 | 0.59x | CN¥46.71 Million | CN¥79.85 Million | ▲ +79.4% |
| 2013 | 0.33x | CN¥28.12 Million | CN¥86.24 Million | — |